SAN DIEGO, Oct. 26, 2016 /PRNewswire/ -- Shareholder Rights
Law Firm Johnson & Weaver, LLP, is investigating potential
claims against Bellerophon Therapeutics, Inc., KemPharm, Inc., Neos
Therapeutics, Inc., CommVault Systems, Inc. and Resource Capital
Corp., as detailed below:
Bellerophon Therapeutics, Inc.
Johnson & Weaver, LLP, is investigating potential violations
of federal and state laws by certain officers and directors of
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH).
On February 13, 2015,
Bellerophon's sold 13 million shares of stock in its initial public
stock offering (the "IPO"), raising $60.0
million in new capital. However, since the IPO,
Bellerophon's stock has imploded, on October
25, 2016, the stock closed at $1.40.
Specifically, Johnson & Weaver's investigation seeks to
determine whether certain statements regarding the Company's
business operations and financial prospects were not as strong as
represented in the Registration Statement
If you are a Bellerophon shareholder and are interested in
learning more about the investigation or your legal rights and
remedies, please contact Jim Baker
(jimb@johnsonandweaver.com) at 619-814-4471. If you email, please
include your phone number.
KemPharm, Inc.
Johnson & Weaver, LLP is investigating potential violations
of federal and state laws by certain officers and directors of
KemPharm, Inc. (NASDAQ: KMPH).
On April 16, 2015, KemPharm's
stock traded as high as $12.33, the
same day the Company sold 5.09 million shares of stock in its
initial public stock offering (the "IPO"), raising nearly
$60 million in new capital.
However, since the IPO, KemPharm's stock has imploded, falling from
its high of $23.63 in September 2015 to close at $3.50 on October 25,
2016.
Recently, on May 5, 2016, KemPharm
announced that the Anesthetic and Analgesic Drug Products Advisory
Committee and the Drug Safety and Risk Management Advisory
Committee of the FDA had reviewed and voted on Apadaz, decisively
by a vote of 16 to 4 that Apadaz should be approved for its
proposed indication of the management of acute pain that requires
an opioid, but voted 18 to 2 against inclusion of abuse-deterrent
labeling for the product. On this news, the stock dropped 56%.
Specifically, Johnson & Weaver's investigation seeks to
determine whether certain statements regarding the Company's
business metrics and financial prospects were not as strong as
represented in the Registration Statement.
If you are a KemPharm shareholder and are interested in
learning more about the investigation or your legal rights and
remedies, please contact Jim Baker
(jimb@johnsonandweaver.com) at 619-814-4471. If you email, please
include your phone number.
Neos Therapeutics, Inc.
Johnson & Weaver, LLP is investigating potential violations
of federal laws by certain officers and directors of Neos
Therapeutics, Inc. (NASDAQ:NEOS).
On July 23, 2015, Neos sold 4.8
million shares of stock in its initial public stock offering (the
"IPO"), raising $72.0 million in new
capital. However, since the IPO, Neos' stock has imploded,
falling from a high of $27.09 in
August 2015 to close at $6.27 on October 25,
2016.
Specifically, Johnson & Weaver's investigation seeks to
determine whether certain statements regarding the Company's
business metrics, operations and financial prospects were not as
strong as represented in the Registration Statement.
If you are a Neos shareholder and are interested in learning
more about the investigation or your legal rights and remedies,
please contact Jim Baker
(jimb@johnsonandweaver.com) at 619-814-4471. If you email, please
include your phone number.
CommVault Systems, Inc.
Johnson & Weaver, LLP, is investigating potential violations
of federal and state laws by certain officers and directors of
CommVault Systems, Inc. (NASDAQ:CVLT).
On September 30, 2016, a federal
court denied a motion to dismiss a securities fraud class action
filed against CommVault and certain executives. CommVault provides
data and information management software applications and related
services in North America,
Europe, Australia and Asia.
The Complaint alleges that during the Class Period, CommVault
and certain of its senior executives violated provisions of the
Exchange Act by issuing false and misleading press releases,
financial statements, filings with the Securities and Exchange
Commission ("SEC"), and statements during investor conference
calls. CommVault derives about half of its annual revenue from
licensing its software applications, with the remaining half of the
Company's revenue coming in the form of services and maintenance
revenue. The complaint alleges CommVault misrepresented revenue
growth by booking and subsequently recognizing deferred software
licensing revenue to mask slowing revenue growth, while at the same
time denying that revenue growth was in fact decelerating. The
Company also misrepresented that it was increasing investments in
its sales force and hiring more sales employees in order to
continue to drive growth through the fiscal year 2014 and
beyond. As a result of these misrepresentations, CommVault
stock traded at artificially inflated prices during the Class
Period.
If you have held CommVault shares continuously since at
least May 6, 2013, you may
have standing to hold CommVault harmless from the damage the
officers and directors caused by making them personally
responsible. You may also be able to assist in reforming the
Company's corporate governance to prevent future
wrongdoing.
If you are a CommVault shareholder and are interested in
learning more about the investigation or your legal rights and
remedies, please contact lead analyst Jim
Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you
email, please include your phone number.
Resource Capital Corp.
Johnson & Weaver, LLP, is investigating potential violations
of federal and state laws by certain officers and directors of
Resource Capital Corp. (NYSE:RSO).
On October 5, 2016, a federal
court denied a motion to dismiss a securities fraud class action
filed against Resource Capital and certain executives. Resource
Capital is a diversified real estate investment trust, primarily
focuses on originating, holding and managing commercial mortgage
loans and other commercial real estate-related debt and equity
investments in the United
States.
The complaint alleges, throughout the Class Period, October 31, 2012 and August 5, 2015, Resource Capital and certain of
its senior executives deceived public investors by failing to alert
them of a particularly risky and dangerous loan within their
portfolio. The loan in question was a mezzanine loan secured by a
number of luxury hotels (the "Mezzanine Loan"). When
initially acquired in 2007, the Mezzanine Loan was secured by 13
hotels owned by The Blackstone Group ("Blackstone"). Three of
the hotels serving as collateral were located in Puerto Rico and as time progressed, these
three hotels came to be the only three assets securing the
Mezzanine Loan. Defendants never disclosed this to investors.
Since 2006, however, Puerto Rico's
economy has been suffering from a crippling recession.
If you have held Resource Capital shares continuously
since at least October 31,
2012, you may have standing to hold Resource Capital
harmless from the damage the officers and directors caused by
making them personally responsible. You may also be able to assist
in reforming the Company's corporate governance to prevent future
wrongdoing.
If you are a Resource Capital shareholder and are interested
in learning more about the investigation or your legal rights and
remedies, please contact lead analyst Jim
Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you
email, please include your phone number.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder
rights law firm with offices in California, New
York and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonandweaver.com. Attorney advertising. Past results
do not guarantee future outcomes.
Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com
Logo - http://photos.prnewswire.com/prnh/20160211/332409LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/johnson--weaver-llp-initiates-investigations-of-bellerophon-therapeutics-inc-kempharm-inc-neos-therapeutics-inc-commvault-systems-inc-and-resource-capital-corp-300351599.html
SOURCE Johnson & Weaver, LLP